Nishida Yu, Hosomi Shuhei, Kobayashi Yumie, Nakata Rieko, Ominami Masaki, Nadatani Yuji, Fukunaga Shusei, Otani Koji, Tanaka Fumio, Nagami Yasuaki, Taira Koichi, Kamata Noriko, Fujiwara Yasuhiro
Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University Osaka, Osaka 530-0001, Japan.
Healthcare (Basel). 2023 Sep 28;11(19):2642. doi: 10.3390/healthcare11192642.
The coronavirus disease (COVID-19) pandemic has had a considerable impact on the global healthcare system and potentially the clinical course of patients with inflammatory bowel disease (IBD). Although IBD is a chronic disease, its therapy (except steroid therapy) does not increase the risk of contracting or aggravating COVID-19. However, the clinical course of patients is significantly influenced by environmental factors. Social restrictions due to the pandemic or the fear of contracting the virus have influenced lifestyle and psychosocial behaviors that may worsen the clinical course of patients with IBD. This narrative literature review summarizes the current evidence on the impact of the COVID-19 pandemic on the lifestyle and psychosocial behaviors of patients with IBD. The COVID-19 pandemic negatively affected the lifestyle and psychosocial behaviors of patients with IBD. Furthermore, patients with IBD failed to maintain medication adherence, thus affecting the clinical course of their condition.
冠状病毒病（COVID-19）大流行对全球医疗系统产生了重大影响，并可能影响炎症性肠病（IBD）患者的临床病程。尽管IBD是一种慢性病，但其治疗（类固醇治疗除外）不会增加感染或加重COVID-19的风险。然而，患者的临床病程受到环境因素的显著影响。大流行导致的社会限制或对感染病毒的恐惧影响了生活方式和心理社会行为，这可能会使IBD患者的临床病程恶化。这篇叙述性文献综述总结了当前关于COVID-19大流行对IBD患者生活方式和心理社会行为影响的证据。COVID-19大流行对IBD患者的生活方式和心理社会行为产生了负面影响。此外，IBD患者未能坚持服药，从而影响了他们病情的临床病程。
